Overcoming Radioiodine-Resistant Thyroid Cancer through Combination of Multi-Targeted Therapy and Gene Editing
Background
Thyroid cancer is the most common endocrine malignancy. Early differentiated cancers can be effectively managed with surgery, radioactive iodine therapy, and thyroid-stimulating hormone (TSH) suppression. Chemotherapy or external beam radiation may also be used depending on the clinical scenario.
In contrast, tumors that lose iodine responsiveness, metastasize, or progress to undifferentiated anaplastic carcinoma become resistant to conventional therapies, leading to a sharp decline in survival rates. This has underscored the urgent need for breakthrough strategies to overcome resistance.
Recent genomic analyses have elucidated the molecular pathways and key mutated genes involved in thyroid carcinogenesis. Notably, aberrant activation of the mitogen-activated protein kinase (MAPK) and phosphatidylinositol 3-kinase/protein kinase B/mammalian target of rapamycin (PI3K/AKT/mTOR) signaling pathways has been identified as a central mechanism. Additionally, mutations in BRAF, RAS, RET, and the telomerase reverse transcriptase (TERT) promoter have been shown to accelerate resistance.
Key Findings
This study comprehensively reviews targeted therapies and next-generation platform technologies aimed at overcoming the challenges of refractory thyroid cancer. The core strategy involves combining signal pathway inhibitors with gene control technologies that alter cellular properties.
First, redifferentiation therapy, which restores iodine uptake by blocking cancer cell signaling pathways, has drawn significant attention. Administering selective RET or BRAF/MEK inhibitors to undifferentiated cancer cells can revert them to a state capable of iodine absorption. This is combined with radioactive iodine to enhance treatment efficacy.
Combination therapy with immune checkpoint inhibitors, which activate immune cells to attack cancer, is also highlighted as an alternative. The use of targeted therapies alongside immune checkpoint inhibitors has been shown to improve the tumor microenvironment and enhance immune cell activity, offering a new pathway for patients who do not respond to monotherapies.
Furthermore, genome control technologies such as CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) gene editing and ribonucleic acid (RNA) therapeutics have been integrated. Representative approaches include removing resistance-mediating mutated genes using gene scissors or suppressing abnormal protein expression with RNA therapeutics. Oncolytic viruses that selectively destroy cancer cells and nanoparticle-based drug delivery systems are also recognized as key factors in maximizing therapeutic efficiency.
Finally, advances in radiopharmaceuticals are notable. Peptide receptor radionuclide therapy, which targets receptors on cancer cells, and alpha-particle radiotherapy, which emits high energy, are being increasingly adopted. These technologies are achieving precise targeting of surrounding cancer cells without damaging normal tissue.
Significance and Outlook
The combination therapies introduced in this study demonstrate a paradigm shift in thyroid cancer treatment toward personalized medicine. Precision therapies tailored to the genetic profile and mechanisms of individual tumors are significantly improving response rates and reducing side effects. This marks the arrival of a new era in precision medicine, where treatment regimens are optimized for each patient.
However, several challenges remain before these therapies can be widely adopted. Combination therapies may introduce new side effects due to cumulative toxicity from individual drugs. For CRISPR gene editing and RNA therapeutics, further improvements in safe and efficient delivery to target cells are essential. High treatment costs and complex manufacturing processes remain barriers to widespread implementation.
Going forward, the safety of these advanced technologies must be rigorously validated through clinical trials. Continued research is needed to identify optimal combinations and dosing schedules that overcome drug resistance. With the accumulation of clinical data, these approaches are expected to significantly improve survival and quality of life for patients with refractory thyroid cancer.
The most prevalent endocrine cancer is thyroid cancer. It may act in a very disparate manner; ranging between slow growing, well differentiated tumours to an aggressive anaplastic subtype. Initial treatment with standard therapy, surgery, radioactive iodine, the thyroid-stimulating hormone inhibition and in some cases, chemotherapy or external-beam radiations are effective with the differentiated cancers at the early stages. Nevertheless, there is no choice with tumours, which become unresponsive to iodine, metastasized, or un- differentiated. Recent developments in molecular oncology have elucidated the genetic alterations that contribute to thyroid cancer, in particular, the MAPK and PI3K/AKT/mTOr pathways, and BRAF, RAS, RET, and TERT promoter mutations. The current review summarizes the changing therapeutic environment of thyroid cancer that includes established targeted medicines and novel developments. These are immune checkpoint inhibitors, redifferentiation based on reinstatement of iodine uptake, selective RET and BRAF/MEK, RNA-based therapeutics, CRISPR gene editing, oncolytic virotherapy, peptide receptor radionuclide therapy, alpha-particle radiotherapy, and nanotechnology-based drug delivery systems. A combination regimen involving molecular targeting and immunotherapy or radioactive iodine is also improving the disease in advanced disease. Collectively, the advances are an indication of a transition to the personalized, mechanism-driven treatment strategies that would prolong the survivability of patients with advanced thyroid cancer, conquer resistance, and reduce systemic toxicity.
In clinical practice, these findings can be immediately applied to develop patient-tailored treatment strategies. For example, patients with advanced thyroid cancer who are found to have BRAF or RET mutations through companion diagnostics can first receive targeted therapies, followed by monitoring of gene expression trends. If the patient develops drug resistance and a decline in iodine uptake is observed, redifferentiation-inducing agents that restore cellular differentiation by blocking signaling pathways can be promptly added to the regimen. This approach could potentially return non-responsive patients to a state where they can once again benefit from radioactive iodine therapy. From the pharmaceutical and biotechnology industry perspective, the development of next-generation drug delivery platforms combining gene editing technologies with oncolytic viruses is expected to gain momentum.